Colchicine administration for percutaneous coronary intervention: A meta-analysis of randomized controlled trials

Analysis (5 RCTs; n=5526) found colchicine may reduce major adverse cardiovascular events (OR 0.78; 95% CI 0.62 to 0.97; P=0.02), but with no impact on mortality (0.89; 0.60-1.32), MI (0.88; 0.67-1.17), serious adverse events (0.71; 0.31-1.61), or restenosis (1.02; 0.63-1.64).

Source:

The American Journal of Emergency Medicine